These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15669876)

  • 1. Extended anticoagulation therapy for the primary and secondary prevention of venous thromboembolism.
    Blanchard E; Ansell J
    Drugs; 2005; 65(3):303-11. PubMed ID: 15669876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of anticoagulation therapy for venous thromboembolism.
    Bounameaux H; Perrier A
    Hematology Am Soc Hematol Educ Program; 2008; ():252-8. PubMed ID: 19074092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended therapy for primary and secondary prevention of venous thromboembolism.
    Conway SE; Marcy TR
    J Pharm Pract; 2010 Aug; 23(4):313-23. PubMed ID: 21507831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticoagulation strategies in patients with deep vein thrombosis and pulmonary artery embolisms].
    Radke PW; Möckel M
    Herz; 2018 Feb; 43(1):34-42. PubMed ID: 29247268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Geerts WH; Pineo GF; Heit JA; Bergqvist D; Lassen MR; Colwell CW; Ray JG
    Chest; 2004 Sep; 126(3 Suppl):338S-400S. PubMed ID: 15383478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Benefit/risk ratio analysis from a possible anticoagulation of asymptomatic deep venous thrombosis in major orthopedic surgery].
    Barrellier MT; Samama CM
    J Mal Vasc; 2013 May; 38(3):178-84. PubMed ID: 23415379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants.
    DeLoughery TG
    Crit Care Clin; 2005 Jul; 21(3):497-512. PubMed ID: 15992670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
    Reynolds NA; Perry CM; Scott LJ
    Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery.
    Bergqvist D
    Vasc Health Risk Manag; 2006; 2(4):365-70. PubMed ID: 17323590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prevention of Venous Thromboembolism in Surgical Patients.
    Hansrani V; Khanbhai M; McCollum C
    Adv Exp Med Biol; 2017; 906():1-8. PubMed ID: 27620304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
    Whang PG; Lieberman JR
    Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis.
    Prandoni P; Vedovetto V; Ciammaichella M; Bucherini E; Corradini S; Enea I; Cosmi B; Mumoli N; Visonà A; Barillari G; Bova C; Quintavalla R; Zanatta N; Pedrini S; Villalta S; Camporese G; Testa S; Parisi R; Becattini C; Cuppini S; Pengo V; Palareti G;
    Thromb Res; 2017 Jun; 154():35-41. PubMed ID: 28407492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging options in the management of venous thromboembolism.
    Jaffer AK; Brotman DJ; Michota F
    Cleve Clin J Med; 2005 Apr; 72 Suppl 1():S14-23. PubMed ID: 15853175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of venous thromboembolism in the elderly.
    Spyropoulos AC; Merli G
    Drugs Aging; 2006; 23(8):651-71. PubMed ID: 16964988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis for thromboembolism in hospitalized medical patients.
    Famularo G; Minisola G; De Simone C
    N Engl J Med; 2007 Jul; 357(3):305; author reply 305-6. PubMed ID: 17644834
    [No Abstract]   [Full Text] [Related]  

  • 20. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.